Taiwan's Industrial Technology Research Institute (ITRI) and local biotechnology company Vita Genomics Inc. have announced that they will be cooperating in providing pharmacogenomics contract services to the global pharmaceutical and biotech community.
According to the announcement, ITRI and Vita Genomics will be uniting their strengths in pharmacogenomics and pharmacoproteomics, offering streamlined, customized or turnkey services for pharmacogenomics clinical trials.
According to Dr. Chung-Cheng Liu, the acting general director of the Biomedical Engineering Research Laboratories (BEL) of ITRI, through a multiple disciplinary research team, ITRI has established high-throughput proteomic and data analysis technology platforms and has successfully constructing six proteome databases.
Vita Genomics has established high-throughput sequencing, genotyping and gene expression profiling facilities and techniques, with the entire pipeline monitored by quality assurance and quality control processes.
ITRI and Vita Genomics both have also obtained the Taiwan Accreditation Foundation (TAF) ISO 17025 Lab certification, and followed GLP principles as well as FDA and ICH guidelines to conduct all the services.
Dr. Ellson Chen, president and CEO of Vita Genomics said, “The alliance will integrate company's capabilities in genomics and gene expression profiling with the strengths in proteomics of ITRI, providing a complete turn-key solution for global pharmaceutical companies.”